secwatch.observer — SEC 8-K summary
======================================

Issuer:     Charlotte's Web Holdings, Inc. (CWBHF)
CIK:        0001750155
Form:       8-K
Filed at:   2023-04-07T23:59:59+00:00
Accession:  0001279569-23-000434
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charlotte's Web forms JV with BAT and AJNA to develop FDA-approved hemp botanical drug
--------------------------------------------------------------------------------

- BAT invests $10M for 20% preferred equity; Charlotte's Web and AJNA each hold 40% voting common.
- JV plans FDA IND filing and Phase I clinical trial in 2023 targeting a neurological condition.
- Dr. Orrin Devinsky, lead Epidiolex investigator, to head JV clinical and regulatory strategy.
- BAT is a related party due to its $56.8M convertible debenture; JV exempt from formal valuation and minority approval.
- Charlotte's Web contributes proprietary hemp IP and clinical data; AJNA provides lab and regulatory services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750155/000127956923000434/0001279569-23-000434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750155/000127956923000434/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001279569-23-000434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer